# AnTolRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antolrx

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.antolrx.com
- Total disclosed funding: $4M
- Latest round: Series A (Sep 8, 2016)
- Investors on record: 3

## About

Founded in 2015 and based in Cambridge, Massachusetts, AnTolRx, Inc. develops proprietary pharmaceuticals, that target pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype in order to treat diseases.

## Funding rounds

- Series A, Sep 8, 2016, $4M — Pfizer Inc., Orion Equity Partners, JDRF T1D Fund

## Investors

- Pfizer Inc. — Series A
- Orion Equity Partners — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A